Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : Says It Has Filed For U.S. FDA Emergency Authorization Of Its Covid-19 Vaccine

11/30/2020 | 06:17pm EST

Nov 30 (Reuters) - Moderna Inc:

* MODERNA SAYS IT HAS FILED FOR U.S. FDA EMERGENCY AUTHORIZATION OF ITS COVID-19 VACCINE Further company coverage:


© Reuters 2020
All news about MODERNA, INC.
01/23MODERNA : U.S. CDC says 41.4 mln doses of COVID-19 vaccines distributed, 20.5 ml..
RE
01/22PFIZER : Provinces doing 'extraordinary' job to avoid wasting doses of COVID-19 ..
AQ
01/2239.9 MLN DOSES OF COVID-19 VACCINES : U.s. cdc
RE
01/22CDC : 10 life-threatening reactions linked with Moderna COVID-19 vaccine
AQ
01/22MODERNA : Lucky few hit COVID-19 vaccine jackpot for rare extra doses
AQ
01/22MODERNA : Severe allergic reactions to Moderna vaccine appear rare -CDC report
RE
01/22AstraZeneca's initial EU delivery volumes of COVID-19 vaccine to fall short
RE
01/22MODERNA : BofA Securities Adjusts Moderna PT to $140 From $130, Maintains Neutra..
MT
01/22Where Our Current Covid-19 Vaccination Rate Will Take Us
DJ
01/22Studies of South African Coronavirus Strain Raise Concerns About Immune Respo..
DJ
More news
Financials (USD)
Sales 2020 512 M - -
Net income 2020 -571 M - -
Net cash 2020 2 597 M - -
P/E ratio 2020 -107x
Yield 2020 -
Capitalization 51 846 M 51 846 M -
EV / Sales 2020 96,2x
EV / Sales 2021 4,40x
Nbr of Employees 1 100
Free-Float 90,0%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 137,27 $
Last Close Price 131,02 $
Spread / Highest target 41,2%
Spread / Average Target 4,77%
Spread / Lowest Target -47,3%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.25.41%51 846
LONZA GROUP AG5.34%50 271
CELLTRION, INC.-13.65%38 245
IQVIA HOLDINGS INC.3.58%35 582
SEAGEN INC.4.35%33 059
HANGZHOU TIGERMED CONSULTING CO.,LTD13.79%24 266